Marc A.  Stapley net worth and biography

Marc Stapley Biography and Net Worth

CEO & Director of Veracyte
Marc Stapley became Chief Executive Officer of Veracyte on June 1, 2021, and also serves on the company’s board of directors.

Mr. Stapley has deep experience in the genomic diagnostics industry, including significant expertise building and leading complex global operations. Prior to joining Veracyte, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021. Under Mr. Stapley’s leadership, Helix built one of the largest COVID-19 testing labs in the United States and became a national leader in viral surveillance.

Prior to Helix, Mr. Stapley served in key executive leadership positions at Illumina, the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. While at Illumina, he served as Chief Financial Officer, Chief Administrative Officer, and Executive Vice President over the course of seven years, where he led many functions including G&A, corporate strategy, business development, population genomics and government affairs.

Before joining Illumina, Mr. Stapley was Senior Vice President, Finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts for key acquisitions and providing oversight to the company’s largest technology investment program. Prior to that he served in a variety of senior finance roles at Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand.

Mr. Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales. He is a member of the board of directors of Helix, Glaukos (GKOS), and Premier Food Concepts.

How old is Marc A. Stapley?

Mr. Stapley is currently 54 years old. There are 6 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Marc A. Stapley's age.

How do I contact Marc A. Stapley?

The corporate mailing address for Mr. Stapley and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at keith@veracyte.com. Learn More on Marc A. Stapley's contact information.

Has Marc A. Stapley been buying or selling shares of Veracyte?

Marc A. Stapley has not been actively trading shares of Veracyte during the last quarter. Learn More on Marc A. Stapley's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 88,392 shares worth more than $2,810,829.26. The most recent insider tranaction occured on February, 3rd when CFO Rebecca Chambers sold 527 shares worth more than $23,108.95. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 2/3/2025.

Marc A. Stapley Insider Trading History at Veracyte

See Full Table

Marc A. Stapley Buying and Selling Activity at Veracyte

This chart shows Mr. Marc A. Stapley's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $30.12
Low: $29.65
High: $31.07

50 Day Range

MA: $37.57
Low: $30.12
High: $46.14

2 Week Range

Now: $30.12
Low: $18.61
High: $47.32

Volume

710,014 shs

Average Volume

835,914 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8